Advertisements

Оргил

Quick links to important sections

Оргил

Selected form

Advertisements
Advertisements

Method of action: Antiprotozoal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Оргил

Property Description
Active ingredient Ornidazole
Form Film-coated tablet, Solution for infusion
Pharmacological class Antibacterial and Antiprotozoal Agent
General purpose Combats anaerobic bacteria and protozoan infections
Origin Synthetic (Nitroimidazole derivative)

Оргил is a prescription-only pharmaceutical preparation whose identity is defined by the sole active substance, Ornidazole. It is a synthetic, single-ingredient agent developed for systemic treatment against specific types of pathogens. The drug is classified into multiple therapeutic groups, reflecting its broad anti-infective capacity.

What is the Active Ingredient in Оргил and Its Chemical Class?

The active compound in this medication is Ornidazole, which is chemically recognized as a nitroimidazole derivative, with the molecular formula C7H10ClN3O3. Ornidazole is a synthetic substance. This classification places it within a specialized group of anti-infective agents whose efficacy is recognized for targeting certain anaerobic organisms. This chemical distinction differentiates its action profile from many other broad-spectrum antimicrobial agents.

Pharmacological Classification and General Purpose of Ornidazole

Оргил is categorized as both an antibacterial and an antiprotozoal agent. This dual classification confirms its general therapeutic purpose is to combat infections caused by susceptible pathogens, including anaerobic bacterial infections and specific protozoan infections. The functional mechanism involves the drug being activated within the target microbial cell, which leads to the formation of highly reactive cytotoxic products that damage the organism's DNA, preventing cell growth and division. This specific anti-anaerobic property makes it a commonly used agent in contexts requiring the elimination of pathogens that thrive in low-oxygen environments.

What Form Does Оргил Take for Systemic Use?

Ornidazole is manufactured for systemic use, meaning the medication is intended to reach infectious sites throughout the body via the bloodstream. The most common physical presentation is a film-coated tablet intended for oral administration. The drug is also prepared as an aqueous solution for intravenous injection, which serves as a specialized route of administration to ensure immediate systemic availability in medical settings.

Regulatory References

  1. World Health Organization
Advertisements

What side effects are possible with Оргил?

Possible Side Effects and Safety Information

The safety profile of Оргил (Elagolix) is defined by a set of common adverse reactions and several important safety risks documented in official regulatory sources.

Serious and Clinically Significant Risks

  • Bone Loss (Decreased Bone Mineral Density): A dose-dependent decrease in bone mineral density (BMD) has been reported, with the loss being greater with increased duration of use. This effect may not be fully reversible after treatment discontinuation. The drug is contraindicated in women with known osteoporosis.
  • Hepatic Injury: Elevations in liver enzymes (hepatic transaminases) have been observed, requiring monitoring. The drug is contraindicated in patients with severe hepatic impairment (Child-Pugh C).
  • Psychiatric Events: Suicidal ideation, suicidal behavior, and worsening of mood disorders have been reported. Patients experiencing new or worsening depression, anxiety, or other mood changes should be evaluated.
  • Hypersensitivity: Severe allergic reactions, including anaphylaxis and angioedema, are possible.

Common Adverse Reactions

The most commonly reported adverse reactions (occurring in over 5% of patients in clinical trials) often involve the nervous and reproductive systems, including:

  • Hot flushes and night sweats
  • Headache
  • Nausea
  • Insomnia
  • Amenorrhea (absence of menstruation)
  • Anxiety and mood changes
  • Arthralgia (joint pain)

Contraindications and Safety Limitations

Оргил is contraindicated in women who are pregnant or may become pregnant, as exposure may increase the risk of early pregnancy loss. It is also contraindicated in those with known osteoporosis, severe hepatic impairment, and in combination with strong inhibitors of the OATP1B1 transporter (e.g., cyclosporine, gemfibrozil) due to the risk of increased drug exposure. Patients must use effective non-estrogen containing contraception during and for a specified time after treatment.

Advertisements

Overdose and Emergency Response

The official regulatory labeling for Оргил (Relugolix) does not define a specific clinical manifestation profile resulting from the ingestion of an excessive dose, focusing instead on the escalation of known severe risks.

When to Seek Help

Regulatory documents mandate that individuals get emergency medical help right away if they experience signs of a severe allergic reaction (hypersensitivity). These critical symptoms include swelling of the face, lips, throat, or tongue (angioedema), difficulty breathing, or the rapid onset of widespread hives. In such emergency scenarios, the prescribing information advises that the medication be withheld or discontinued as clinically appropriate.

Management and Monitoring

The primary severe risks that may be exacerbated by overdose involve the cardiovascular system, particularly the potential for QTc interval prolongation, and serious hypersensitivity reactions. As no specific antidote is known, the official management is symptomatic and supportive treatment. Clinical guidance requires considering periodic monitoring of electrocardiograms (ECG) and the necessary correction of electrolyte abnormalities. Official warnings also caution that patients with severe renal impairment may experience up to a two-fold increase in drug exposure, which is a key factor for medical oversight during an overdose scenario.

Advertisements

Therapeutic Uses of Оргил

Quick Facts

  • Primary Use: Management of advanced prostate cancer.
  • Benefit: Is utilized as part of a therapeutic regimen to help address the condition.

What Оргил Treats: Main Uses and Benefits

Оргил (Relugolix) is indicated for the treatment of adult patients with advanced prostate cancer. This medication is a component of a therapeutic regimen designed to manage the progression of the disease. It is utilized to help address the specific hormonal factors associated with the condition.

Its main purpose is to support the management of the disease state in this patient population, providing a treatment option consistent with the current standards of care. This approach may help to reduce the presence of disease markers.

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use ORILISSA (elagolix)

Official regulatory documents establish clear eligibility rules for ORILISSA use, primarily defining absolute contraindications and specific population restrictions.

Absolute Exclusions (Contraindications)

ORILISSA must not be used by women who are pregnant or attempting to conceive, have known osteoporosis, or have severe hepatic impairment (Child-Pugh Class C). Use is also prohibited for patients with a known hypersensitivity to the drug or those taking strong OATP1B1 inhibitors.

Condition-Based and Age-Related Restrictions

Population Category Regulatory Status
Pediatric Patients (Under 18) Safety and effectiveness are not established in this population.
Moderate Hepatic Impairment Restricted use: Limited to the 150 mg once-daily dose, with a maximum treatment duration of six months.
Pregnancy/Lactation Contraindicated in pregnancy. Insufficient data exist regarding use during breastfeeding.

Treatment duration is also restricted based on the dose, regardless of underlying conditions, with the 150 mg dose limited to 24 months and the 200 mg dose limited to 6 months total.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Ornidazole, the active ingredient in Оргил, based on both metabolic and pharmacodynamic mechanisms. The key constraint is the product's ability to inhibit the metabolic enzyme CYP2C9.

Entity Description based on Regulatory Sources
Medicinal product categories with documented interactions: Coumarin-type oral anticoagulants, specific non-depolarizing muscle relaxants, and medicines metabolized by CYP2C9.
Specific interacting medicines: Warfarin, Phenytoin, Lithium, 5-Fluorouracil, Vecuronium bromide.
Mechanistic basis of interactions: Pharmacokinetic interaction due to CYP2C9 enzyme inhibition; Pharmacodynamic reinforcement (additive effect).
Interaction-related restrictions: Concomitant use with alcohol (ethanol) is restricted due to the documented risk of a disulfiram-like reaction.

Official interaction statements:

  • Co-administration with oral anticoagulants may result in an enhanced anticoagulant effect due to the inhibition of CYP2C9, which requires official monitoring of coagulation status.
  • The co-administration of Lithium or 5-Fluorouracil is formally stated to increase their plasma concentration due to reduced clearance, a finding documented in prescribing information.
  • Co-administration with Vecuronium bromide may lead to a prolongation of the muscle-relaxing effect.
  • In patients with liver cirrhosis (hepatic impairment), the prolonged elimination half-life is noted as relevant to the potential for increased exposure-related interactions.

The overall interaction structure defines a profile where co-administered drugs requiring metabolic clearance may experience increased exposure, and certain combinations involve pharmacodynamic reinforcement of effect, requiring regulatory caution.

Advertisements

Mechanism of Action

How Оргил Works

Ornidazole functions as an inactive prodrug, with its mechanism relying on selective intracellular activation. The drug is reduced by microbial nitroreductase enzymes (NTRs), which are present only within the low-oxygen (low-redox potential) environments of susceptible anaerobic bacteria and protozoa. This enzyme-driven process transforms the stable Ornidazole molecule into highly reactive nitro radical anions and other unstable intermediates.

These activated species immediately attack essential cellular components, most critically the pathogen's DNA. This chemical interaction causes strand breaks and structural fragmentation in the genetic material, causing irreversible cellular injury. The resulting damage to the genetic code halts replication and transcription, leading to the cessation of proliferation and function, culminating in microbial cell death.

This mechanism demonstrates selective toxicity as the activation step is confined to microbial cells. However, its action is chemically constrained: the active intermediates are rapidly neutralized (re-oxidized) by O2, meaning the mechanism is substantially attenuated in well-oxygenated tissues and is physiologically constrained to anaerobic environments.

Advertisements

Dosage and Administration Information

Administration Guidelines for Оргил (Relugolix)

The administration of Оргил is defined by a two-phase schedule, designed for consistent systemic delivery. The medicine is provided as a 120 mg film-coated tablet for oral use only.

Standard Dosing and Schedule

The treatment begins with a single 360 mg loading dose on the first day of administration. This is followed by a 120 mg maintenance dose taken once daily thereafter. For consistent dosing, the medicine should be taken at approximately the same time each day, and it can be taken with or without food. The tablets are intended to be swallowed whole and not crushed or chewed to maintain the intended release profile.

Procedural Rules for Interruptions

Standard procedures are described for handling interruptions in therapy.

Situation Required Action
Missed Dose If the missed dose is noted within 12 hours of the usual time, it should be taken immediately; otherwise, the dose should be skipped, and the regimen should resume with the next scheduled dose.
Treatment Interruption If the medicine is stopped for more than seven days, treatment is restarted by taking the full 360 mg loading dose on the first day, followed by the 120 mg daily maintenance dose.

Population and Interaction Guidance

No routine dose adjustment is required for older adults, patients with mild to moderate hepatic impairment, or those with severe renal impairment. However, if the patient is concurrently taking a combined P-gp and strong CYP3A inducer, the maintenance dose is increased to 240 mg once daily until the inducer is discontinued.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Оргил (Relugolix)


Evidence for Use in Advanced Prostate Cancer

The foundational research for Оргил was studied for its evaluation as an oral agent used in androgen deprivation therapy (ADT) for adult patients with advanced prostate cancer. The most important research comes from large, international, randomized, open-label Phase 3 clinical trials. These studies were designed to compare the agent with a standard injectable therapy that is already widely used for this condition, allowing researchers to examine the agent's characteristics and measured effects under controlled conditions.

Research was primarily applied in studies examining patient-reported experiences and monitoring physiological strain related to the disease. The primary research focus was on outcomes related to physiological imbalance, specifically the examination of achieving and maintaining castration levels—meaning the suppression of testosterone below a certain low threshold. Studies also monitored shifts in important biomarkers, such as Prostate-Specific Antigen (PSA) levels, which are routinely checked as part of managing the condition.


What Research Outcomes Were Measured

The core of the research focused on outcomes related to systemic or functional imbalance by monitoring the speed and level of testosterone suppression observed in patients receiving Оргил. The main randomized trials describe measurements related to testosterone suppression, indicating that this pattern was observed in the study populations over the evaluation period. Data show patterns related to the onset of testosterone suppression observed at early time points in the first weeks of the study.

Furthermore, studies monitored outcomes reflecting daily functioning by incorporating patient-reported outcomes (PROs) to understand perceived discomfort and the overall quality of life experienced by patients during the study period. Research was also conducted to monitor the time it took for the disease to show signs of progression.


What Remains Uncertain About the Research

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Key research limitations include the duration of initial follow-up. The long-term outcome data on disease progression and overall survival over many years are not fully established because the follow-up durations were limited in the initial core studies. Furthermore, the long-term cardiovascular outcome data remains an area of ongoing study. Comparative evidence is lacking, as pivotal trials primarily compared Оргил to only one standard injectable treatment.

Key Studies & References

  1. A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO Study) - ClinicalTrials.gov NCT03085095
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Оргил (FAQ)


Q: How quickly should I expect Оргил to start working?

A: The time it takes to observe the effects of this medication varies depending on the specific condition being addressed. For its use in advanced prostate cancer, clinical studies indicate that physiologic changes, such as testosterone suppression, were noted in clinical trials to occur early in the first few weeks of the treatment period.

Q: Why do some people say Оргил didn't work for them?

A: Clinical trials document expected response rates based on the study populations, but outcomes can naturally vary from person to person. Official research on the drug describes general group patterns observed in studies and does not guarantee results for any specific individual.

Q: How long does a course of Оргил usually last?

A: The total length of a treatment course is dependent on the condition for which the medication is prescribed. For certain uses (Elagolix), official documents specify maximum treatment durations of either 6 months or 24 months based on the dose. Duration for anti-infective use (Ornidazole) is typically defined by the type of infection being treated.

Q: What do clinical studies say about the effectiveness of Оргил?

A: Clinical studies measured the drug's effectiveness against specific physiological markers. For instance, in advanced prostate cancer, its effectiveness was evaluated based on the suppression of testosterone. For its anti-infective applications, official information describes effectiveness based on the drug’s observed activity against susceptible anaerobic pathogens, as shown in regulatory clinical data.

Q: How does the body process or break down Оргил?

A: Official pharmacokinetic information explains how the body handles the drug through a process of absorption, metabolism, and excretion. This process often involves the liver, where it may interact with enzymes like CYP2C9 (Ornidazole). The specific timing for how quickly the body breaks down and removes the drug is detailed in regulatory documents.

Q: How long does Оргил stay in your system after stopping it?

A: The time the medication remains in the system is defined by its elimination half-life, a key piece of information found in official pharmacokinetic data. This data determines the time required for the body to remove the substance and is used to inform the overall prescribing guidance.

Q: Does Оргил interact with herbal remedies like St. John's Wort?

A: Official drug interaction guidance notes that this medication interacts with strong inducers of specific metabolic pathways, including P-gp and CYP3A. Strong herbal agents, such as St. John's Wort, fall into this category. Interaction with these substances is noted to potentially necessitate a temporary adjustment to the prescribed daily dose, as defined in the official documentation.

Q: Is it possible for Оргил to cause stomach upset?

A: Regulatory documents list adverse reactions observed in clinical trials. Nausea is listed among the common side effects. Additionally, official information indicates that other forms of gastrointestinal discomfort, such as vomiting or diarrhea, have been reported in study populations.

Q: What are the main things I should discuss with a healthcare provider before starting Оргил?

A: Regulatory documents highlight several key factors that require evaluation before beginning treatment. These typically include the patient's current pregnancy status, bone density history, any prior or existing mood or psychiatric disorders, and the presence of severe liver impairment. A comprehensive review of all prescription and non-prescription medications being taken is also noted as a key prerequisite for use, according to regulatory documents.

Q: Is Оргил used for pain relief?

A: The official regulatory documents define the approved therapeutic purposes for this medication. These uses include treating specific types of infections (Ornidazole) and serving as a therapy for advanced prostate cancer (Relugolix). Pain relief is not cited in the regulatory guidance as an approved indication for this drug.

Q: Is it normal to feel tired after starting Оргил?

A: Clinical trial data documents all adverse reactions reported by patients. Official information indicates that fatigue, or tiredness, has been reported as an adverse event in some individuals who participated in the studies.

Q: Can I drink coffee while taking Оргил?

A: Official drug guidance specifically advises against the concomitant use of alcohol due to the risk of certain adverse reactions. However, regulatory documents do not list any formal restrictions regarding the consumption of coffee or caffeine-containing products.

Q: Is it okay to take common over-the-counter pain relievers with Оргил?

A: The product labeling notes that the drug may interact with other medicines, especially those metabolized by the CYP2C9 enzyme. Because certain common over-the-counter pain relievers can be metabolized by this pathway, official information describes that the use of such products is typically reviewed by a healthcare professional due to potential metabolic interactions.

Q: Are there any specific vitamins or supplements that interact with Оргил?

A: Formal interaction studies focus on potent herbal substances and prescription drugs that affect the metabolic pathways (e.g., CYP2C9 and P-gp) that process the drug. Official guidance states that individuals should ensure their healthcare provider is informed about all supplements being taken to ensure no potential risks related to metabolic pathways are overlooked.

Q: Is Оргил habit-forming or addictive?

A: This medication is not classified by regulatory bodies as a controlled substance. Official prescribing documentation does not contain warnings or information indicating that the drug has potential for abuse or habit-forming properties.

Q: Does Оргил cause weight changes?

A: Changes in body weight have been observed as an adverse reaction in some individuals participating in the clinical studies. This finding is documented in the official adverse reactions section of the product information.

Q: Where can I find the official prescribing information for Оргил?

A: The complete official prescribing information is made publicly available by regulatory bodies. You can typically find these documents through government-run public databases, such as the U.S. National Institutes of Health's DailyMed or the European Medicines Agency's public document library.

Q: Is it true that Оргил can affect blood pressure?

A: Official documents on adverse events list cardiovascular issues, and reports of changes in blood pressure have been noted in some individuals during clinical studies. This type of finding is formally documented in the Warnings and Precautions section of the drug information.

Q: Is there a generic version of Оргил?

A: Whether an approved generic alternative for the drug is available is determined by its regulatory status in a specific region, which relates to patent and approval timelines. This factual information is maintained and updated within official government drug databases.

Q: Why is professional guidance necessary before starting Оргил?

A: This medication is classified as prescription-only. Official classification as a prescription-only drug requires a professional assessment of the patient’s existing health status and potential drug interactions to confirm appropriate use.

Q: Is it safe to drive or operate machinery while taking Оргил?

A: Official product information notes that certain side effects, including headache, anxiety, and insomnia, have been reported in clinical studies. Official warnings note that, due to these potential adverse effects, caution should be exercised regarding driving or operating machinery.

Q: Have there been any recent safety warnings about Оргил?

A: Regulatory authorities continuously monitor the drug’s safety profile post-approval through pharmacovigilance. Any new information that leads to the issuance of public safety updates or warnings is communicated directly and formally through official government alert channels.

Q: What should I do if the side effects of Оргил bother me?

A: The patient counseling section of the official prescribing information indicates that contacting a healthcare provider is recommended if side effects are experienced that are bothersome or persistent. It is also noted as important to seek guidance immediately for severe allergic reactions or new and worsening mood changes.

Q: How is the safety of Оргил monitored after it is approved?

A: The long-term safety of the medication is continuously monitored by regulatory authorities through a process known as pharmacovigilance. This process includes collecting and reviewing reports of adverse effects that occur after the product is available on the market, as well as analyzing data from ongoing post-approval research studies.

Q: Is there a known withdrawal process when stopping Оргил?

A: Official prescribing information notes the potential for a return of the condition's original symptoms following discontinuation of the medication. A formal withdrawal process is only typically documented if the drug is associated with physiological dependence or specific rebound effects, which would be listed in the regulatory warnings.

Advertisements

How should Оргил be stored and disposed of?

How to Store and Dispose of Orgil (Ornidazole)

Orgil (Ornidazole) must be stored according to official labeled requirements to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30 C (86 F); do not freeze.
Protection The product must be protected from light and moisture.
Packaging Keep the medicine in its original container, which must be kept tightly closed.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Orgil must not be disposed of via wastewater or household waste. Disposal should be managed according to local requirements for medicinal products, typically by returning them to a pharmacy or designated collection program. This process helps to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Оргил found in:

A-Z Index: